Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.44 |
| ▸ | PDE4A | P27815 | 9/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375614 | 0.90 | PDE4B (0.55) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL4365529 | 0.80 | PDE4B (0.56) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL4369320 | 0.79 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL8748732 | 0.77 | KMT2A (0.52) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL4369467 | 0.76 | PDE4B (0.53) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL4366148 | 0.76 | PDE4B (0.48) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL3678492 | 0.71 | PDE4B (0.62) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL3680848 | 0.71 | PDE4D (0.54) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL7948373 | 0.70 | ALDH1A1 (0.51) | KMT2AMAPTPOLB | |
| SCHEMBL4363589 | 0.70 | PDE4B (0.46) | PDE4BKMT2APDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885KMT2A 3155/4885PDE4D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.